Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351125 | 0.85 | BACE1 (0.40) | — | |
| SCHEMBL8275897 | 0.81 | BACE1 (0.39) | — | |
| SCHEMBL4698193 | 0.78 | BACE1 (0.40) | KDM1ASLC6A4 | |
| SCHEMBL2871341 | 0.78 | KDM1A (0.41) | KDM1ASLC6A4 | |
| SCHEMBL1420518 | 0.78 | KDM1A (0.59) | KDM1ASLC6A4 | |
| SCHEMBL2876145 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL3001569 | 0.76 | KDM1A (0.57) | KDM1ASLC6A4 | |
| SCHEMBL4697092 | 0.76 | SLC6A4 (0.35) | SLC6A4 | |
| SCHEMBL2871123 | 0.75 | BACE1 (0.39) | — | |
| SCHEMBL2875000 | 0.74 | ICMT (0.37) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4642764-A2 | AZAINDOLE ROCK INHIBITORS | Avicenna Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12286433-B1 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12281115-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12240848-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12116366-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240254124-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240246972-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024145569-A2 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145569-A2 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-12240848-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-12281115-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20240254124-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | KDM1A 682/4885SLC6A4 903/4885 |
| US-12116366-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-12286433-B1 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20240246972-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
| US-20250092038-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885SLC6A4 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.